Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aegis started GMED at Buy today. 10 valuation models support stock's rating:
Fair Value Source
GMED valuation models show big upside before earnings: Valuation
Chart in reversal mode it seems: Good Luck.
mlkr
Globus Medical sees Q4 revs of $100.5 mln vs $97.9 mln Capital IQ Consensus Est (GMED) 12.32 : Co announced preliminary unaudited sales results for the year ending December 31, 2012, in advance of its national sales meeting being held later this week. The co anticipates Q4 sales of $100.5 million, a 14.3% increase over Q4 2011, and full year 2012 sales of $386.0 million, a 16.4% increase over 2011.
"Our business remains robust, and Q4 performance is a testament to the consistent execution of our strategy. We believe we will continue to grow our business at rates significantly above the industry by innovating in rapid response to the needs of our customers and patients, growing our US sales force, and expanding our footprint internationally."
With the " INTRO " on Ihub still showing the " old GMED " information, makes it real hard for anyone to get too excited about buying into the new stock wouldn't you say???
The new company needs to DISTANCE THEMSELVES from the old ticker and information ASAP......IMHO !
GL2A on this new company!
Yes, unfortunately. The new company's IPO opened at $12/share. This company has great potential and a lot of room for growth. They specialize in spinal surgeries. Could be worth more than $50/share one day
Here is the link to the OLD company.........http://www.genomed.com/about-us.html
It does appear the old GenoMed DR. is still alive and well and continuing the SCAM.
Contact him directly using the URL above and you can get the word 1st hand from him if he will talk to you. The site appears to be current as of 2012 so possibly he will buy those shares from you your holding as a fond rememberence of how he put it to hundreds of invstors who unfortunately listened to his lies.
You can also enjoy one of his LAST DITCH EFFORTS in March 2010 to continue the scam after the SEC delisted the stock......
http://genomed.com/companynews/press-releases/78-sec-suspends-trading-in-genomed-shares-companys-response.html
GL2U!
They sure are worthless. The new company would have issued new stock cert. to all shareholders.
GMED closed the doors quite some time ago. The good " for nothing " DR. ended up over seas somewhere pulling his same crap as before last time I checked. Don't know what ever happened to him.
so igeuss our old shares are dead from gmed
I guarantee you if the " DR's name " shows up ANYWHERE in this new company I would avoid it like the plague and run for the HILLS very fast!!!!!
Hope the new company does well and the old con artists from Genomed doen't hang over this new one like a " huge black cloud " on a clear day!!!!
That is the risk a company takes when taking an " old symbol " from a company that bellied up with a boatload of bag holders.
Obviously not the same company.
Hopefully this one does better!!!
Reborn???
Globus Medical Announces Pricing of Initial Public Offering
Date : 08/03/2012 @ 8:46AM
Source : Business Wire
Stock : Globus Med Com USD0.001 A (GMED)
Quote : 0.001 0.0 (0.00%) @ 2:05AM
Globus Medical, Inc. (NYSE:GMED), a leading spinal implant manufacturer, today announced the pricing of its initial public offering of 8,333,333 shares of Class A common stock at a price of $12 per share, consisting of 2,083,333 shares offered by Globus Medical and 6,250,000 shares offered by selling stockholders. In addition, Globus Medical has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of common stock to cover any over-allotments. Closing of the offering is expected to occur on August 8, 2012, subject to customary closing conditions. The shares are expected to begin trading on the New York Stock Exchange today under the symbol GMED.
Dr. David Moskowitz, GenoMed’s CEO
Why would I want to talk to a DAMN LIAR? I would not waste the time or energy with this man. He has not been truthful in any of his dealings with this company and has BS'ed people for many years.
It is a proven fact he has not followed through on his promises. I had emails directly from him in regards to several questions I had about his " findings " from years ago. Plain BS....this man lying about the great things he was doing and working on which not a single investor ever profited from or could even obtain results from. Not one of them ever happened that I am aware of.
He is a scam artist of the worst kind and too bad the IRS & SEC didn't catch up to him. I believe he is out of the country now promoting his BS overseas.
They still have firing squads, stone people and hang people in some countries don't they????? HUMMMMMMM !!
Have you tried contacting Dr. Moscowitz? Is he still talking to shareholders?
The OZ is gone!
No trading is taking place, the doors are closed. I sold my thousands of shares for zip just to get a write off as their is NO MARKET FOR THEM.
This should of happened around 4-5 years ago since it has all been smoke and mirrors.
A CEO ( if you can call him that ) that can't find anyone in the medical industry to even support his antics. They laugh at him....read some of the articles....search for Genomed on the internet. In his case, the SEC should have investigated him along with the IRS.
Lots of people burned by this man....too bad their is not a BLACK LIST FOR CEO's as this clown would lead the list.
Oh well....sub penny stocks....you get what you pay for....and in this case it was a liar at every step of the way.
Why does it take $50,000 to submit financials to the SEC? Couldn't a para legal do it for $50...if there are no really material changes from last year as Doctor Moskey suggested?
Why does it take $50,000 to submit financials to the SEC? Couldn't a para legal do it for $50...if there are no really material changes from last year as Doctor Moskey suggested?
The trouble is, is that it is still trading. It traded today, the suspension was for two weeks and that is over. I think Genomed has to fold, declare BK, or revoke all shares (if they can), none of which they have done.
i guess you didn't know if it is revoked it is not hard at all to take it as a loss. you put it as a sell for zero with your accountant b/c it is not sellable sec revoked. i do it all the time in my computer and submit it to the accountant. if the stock trades again then it is zero basis. no need to give it to the market makers for nothing.
To get it off their account and be able to take a tax loss. I you don't sell it, its hard to take a tax loss.
why would some one dump 730k for nothing?
so on grey sheets now crippled and hobbled. is the charter going to be revoked too? he cannot file the 15c 2-11 with finra?
It traded yesterday and today. It was suspended for two weeks by the SEC, ending yesterday, no matter what the company says it has traded.
moneymade i guess you know gmed is not trading any more. were you paid to promote gmed? or was it your own call down there in bermuda??
SEC Suspends Trading in GenoMed Shares; Company's Response
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314-983-9933
dwmoskowitz@genomed.com
March 4, 2010—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that the Securities and Exchange Commission suspended trading in its shares today because the company is delinquent in its SEC filings.
Dr. David Moskowitz, GenoMed's CEO, said, "We are committed to trading on the Pink Sheets again as soon as possible. The problem is money. In the past, auditors and attorneys have charged us on the order of $50,000 a year to file our SEC reports, even though the reports have been quite simple. In September, 2005, we ran out of money to pay auditors and attorneys. I stopped taking a paycheck from GenoMed in May, 2005. For the past few years, I've been supporting the company out of my retirement money. Although I've been working for free since 2005, I haven't found any attorneys or auditors willing to do so."
Dr. Moskowitz continued, "We're trying to bring money into the company just as single-mindedly as before. We're pursuing joint ventures to develop so-called 'kind' chemotherapy: non-toxic pills that slow cancer down. We're also marketing directly to patients with diabetes, high blood pressure, or emphysema."
Dr. Moskowitz ended by saying, "I remain committed to all the company's investors. I am one myself. Becoming compliant with the SEC again should have the effect of an IPO, with a resultant increase in our share price. Most importantly, I believe in our mission to transform healthcare: to save lives while lowering costs. I continue to believe that it's only a matter of time before word leaks out, especially to Baby Boomers, that we can prevent 90% of kidney failure and save Medicare 10% of its budget. It's not our fault that Medicare doesn't want to."
About GenoMed (www.genomed.com)
GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company recently began a "Dialysis-Free in 5" campaign: it will gladly work with any community in the world that wants to eliminate 90% of dialysis within 5 years. GenoMed hopes to make the St. Louis area dialysis-free by 2015.
been following since 2000. Met Moskowitz in FL at the old DNAP complex. Any thoughts or updates on current OS?
Civil Rights Activist Lawrence Guyot Supports GenoMed
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
Mr. Lawrence Guyot
Editor, Guyot's Newsletter
Tel. 202-332-5157
margaretkibbee@ymail.com
ST. LOUIS—December 21, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that longtime civil rights activist Lawrence Guyot has published GenoMed's story in his monthly newsletter.
The article, entitled "A Modern Day Tuskegee—and What's Really Wrong with U.S. Healthcare" (http://www.genomed.com/images/guyot_dec09nl.pdf) was written by GenoMed's CEO, David Moskowitz MD.
Mr. Guyot, one of the leaders of the civil rights movement, was born in Pass Christian, Mississippi. As a 21 year old student at Tugaloo College in 1960, he helped found SNCC, the Student Nonviolent Coordinating Committee. In 1964, Mr. Guyot directed the Freedom Summer Project in Hattiesburg, Mississippi. That same year, he was elected chairman of the Mississippi Freedom Democratic Party. He was unable to accompany the delegation to the Democratic National Convention in Atlantic City, New Jersey because he was jailed for registering black voters. The MDFP's actions in New Jersey ultimately led to the DNC desegregating future conventions and the party itself.
Mr. Guyot has been featured in a number of documentaries, including Eyes on the Prize, Making Sense of the Sixties, The War on Poverty and Tales of the FBI. In addition to his monthly newsletter, he is a frequent TV guest on CNN and Fox News.
Dr. Moskowitz said, "I am enormously proud to have such a distinguished leader of the civil rights movement stand up for me and my company, GenoMed."
Dr. Moskowitz continued, "My paper showing how to prevent at least 90% of kidney failure was published in September, 2002. Although kidney failure claims the lives of 100,000 Americans every year, it affects African-Americans 5 times more, and Hispanics 3 times more, than whites. Medicare currently spends $40 billion a year on this disease."
Dr. Moskowitz ended by saying, "Hopefully, Mr. Guyot's endorsement will spur Medicare to call me so that together we can rid our country of this awful disease."
Successful promotional campaigns don’t happen by chance.
Gmed need to spend some money to promote ... IMO
GenoMed Partners with The Mane Event to Eradicate Dialysis in St. Louis
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
Gerald Shelton
The Mane Event
8327 Olive Blvd.
St. Louis, MO 63132
Tel. 314.363.0570
bc23@sprint.blackberry.net
ST. LOUIS—November 23, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has begun partnering with St. Louis barbershops and hair salons to keep their customers from going on kidney dialysis.
GenoMed's first partner is The Mane Event. GenoMed placed a $35 blood pressure cuff in the store over the weekend. Owner Gerald Shelton will encourage his customers to check their blood pressure while they're waiting to be served. People with a blood pressure over 120/80 are urged to contact GenoMed. GenoMed is the only company in the world that has published it can prevent kidney failure due to high blood pressure or diabetes, provided that patients are begun on its treatment early.
Mr. Shelton said, "In my own family and my community, I've seen what a silent killer high blood pressure can be. It's time for us to take charge and help each other out. I'm glad a company like GenoMed is reaching out."
Said David Moskowitz MD FACP, GenoMed's CEO and Chief Medical Officer, "I'm thrilled to be working with Mr. Shelton, who saw from the very beginning how useful a blood pressure machine would be for his customers."
Dr. Moskowitz continued, "GenoMed aims to place blood pressure machines in most of the barber shops, beauty shops, and laundromats in the city and county of St. Louis—wherever people have time on their hands. It's impossible to know your blood pressure unless you check it. And it's impossible for blood pressure to hurt you if you treat it right. People need to get in the habit of checking their blood pressure at least once a month."
Dr. Moskowitz ended by saying, "We're making it easier for people with high blood pressure to find out who they are, and to control their pressure better. GenoMed takes its public health obligation very seriously. Ours is the only paper in the medical literature showing that most kidney failure can be prevented. Even if nobody else in healthcare or public health will take the practical steps to eradicate kidney failure, we will."
About GenoMed (www.genomed.com)
GenoMed to MO Gov. Nixon: "We Can Save Medicaid $32.5 M by June."
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—November 16, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™ that is pioneering Next Generation Disease Management, announced today that it can save Medicaid $32.5 million by June, 2010.
Like many states during the current Depression, Missouri's revenues have fallen far short of expenditures. As a result, Governor Jay Nixon has recently cut over $600 million from the state budget, including $32.5 million from Medicaid, primarily by reducing payments to nursing homes and home health agencies.
GenoMed has identified a way to effect the same savings, while actually improving patient outcomes.
Missouri Medicaid currently spends 35% of its total budget on acute-care inpatient hospitalizations, or $1.5 billion. The national average is 25%, meaning that Missouri spends a lot more of its Medicaid budget on hospitalizations than most states. If elderly patients could be kept healthier and out of the hospital, Missouri Medicaid costs could be slashed. GenoMed's cutting-edge, genomics-based medicine can accomplish this.
Said David Moskowitz MD FACP, GenoMed's CEO and Chief Medical Officer, "Two diseases in the elderly consume an extraordinary amount of money: heart failure and emphysema. Every time a patient goes to the Emergency Room for shortness of breath, it costs around $10,000. If they're admitted to the hospital from the ER, it can easily cost $50,000. These patients are easy to identify and to help. We've published how to keep patients with heart failure and emphysema out of the hospital by delaying the progression of their disease."
Dr. Moskowitz ended by saying, "We'd like to be able to prove ourselves here in Missouri, the Show Me state. Next year's budget shortfall is projected to be even worse. WIth healthcare costs rising so fast in the US, and state revenues falling, all 50 Medicaid offices should be interested in GenoMed."
About GenoMed (www.genomed.com)
Why was there any movement on this stock today? And why was it up .0002 rather than down?
For a number of years I've been sending Genomeds website address to various Stock writers sites. I have given them a brief discription about Genomed. I have never received a reply. As a result I have cancelled my Subscriptions. I also sent the same info.several times to a few Doctors websites one bragged to be the largest in America. I received no replys so I say to hell with them.
I think were on our own until more of the masses can learn about Genomed. It's turned out to be a very slow process. Keep the faith as I believe Genomed will be discovered sooner rather than later.
I truly believe in Genomed,for what their doing cannot be ignored much longer.
nextofkin
What can GMED shareholders do to raise our company's stock price?
Thanks for asking!
The best way for our stock price to rise is if people knew about us. As luck would have it, the current healthcare reform debate is a perfect opportunity for that to happen.
President Obama has called for prevention, and cost-cutting.
As far as I can tell, we're the only entity in healthcare that can do both. So this may be our time for national attention.
Specifically, here are two op-ed pieces. If you agree with them, send the links to your friends. If any of your friends are healthcare reporters, so much the better!
http://tinyurl.com/healthcrime
http://tinyurl.com/DavidWashingtonMoskowitz
Dave Moskowitz MD
CEO & CMO
GenoMed, Inc
Prevention is the best move to counter the worsening problem on kidney disease in the country.
Council for Health and Development /philippines
The burden of renal diseases
About 1.2 million Filipinos today are suffering from kidney diseases, requiring either dialysis or a kidney transplant for them to live. Among the leading causes of kidney failure in the country are diabetes (41%), inflammation of the kidney (24%) and high blood pressure (22%).
According to the Department of Health, kidney disease is now one of the top ten causes of death among Filipinos wherein 7,000 die annually due to kidney malfunction. Because of the increasing number of Filipinos with kidney disease, it is now considered among the top seven health problems in the country.
Worldwide, there is also an alarming level of kidney disease with more than 500 million persons suffering from some form of kidney damage. Over 1.5 million of them are kept alive either through dialysis or transplantation. Every year, over 12 million individuals die prematurely of cardiovascular diseases linked to chronic kidney disease.
Costly treatment
In the Philippines, the treatment of kidney diseases is very costly and unaffordable.
Dialysis treatment uses artificial devices to perform the function of the kidney at about 15%, which is enough to sustain life but needs to be performed adequately on a regular basis (2-3 times a week) for life. Patients without sufficient dialysis are weak and show many of the symptoms that led to their diagnosis. Malnourished and unable to work, they tend to survive only until the next dialysis treatment. A patient has to spend P25,000 to P46,000 a month or P300,000 to P552,000 a year for his or her dialysis. Maintenance medication costs about P20,000 a month.
Kidney transplantation offers the best option for patients with kidney failure as shown by foreign and local studies, according to Romina Angangco Danguilan, chair of the NKTI’s Department of Adult Nephrology. In her study, she noted that the quality of life of a transplant patient is superior to one on dialysis. Kidney transplantation cost ranges from P500,000 to a million. Post-operation medication costs about P12,000 a month.
Because treatment is very expensive and draining to the pocket, it was reported that in 2007, only 73% of Filipino patients with kidney failure were able to afford necessary treatment.
No government support
Patients with PhilHealth coverage can only claim half of the cost of their treatment and cash out for the remaining cost. According to National Kidney Transplant Institute, only 15% of the partially-subsidized patients are PhilHealth members.
Poor kidney patients survive through assistance and borrowings from relatives and friends. Many of them had to beg around for funds from politicians and charitable organizations to pay for their treatment. Even patients who can afford admit that the burden of their treatment cost is heavily draining their families’ resources.
Dr. Lyn Almazan-Gomez, former president of the Philippine Society of Nephrologists said that there is no “free treatment” for kidney diseases. “It would be very draining for the government to shoulder treatment costs for renal patients considering the amount involved,” said Dr. Remedios De Belen-Uriarte, Department Manager of the Renal Disease Control Program of the National Kidney Transplant Institute (NKTI). She said that with limited income and resources, even NKTI can hardly afford to expand its services.
The NKTI is the government’s specialty health facility for kidney transplant and kidney-related diseases. In its out-patient hemodialysis unit, about two-thirds of the patients are pay patients who are able to afford the full amount of treatment costs and are given priority in the dialysis treatments. Only one-third of the patients are relatively poor service patients who avail of the discounts on hospital fees and charges given by the social services section but would have to wait for days to acquire a slot in the dialysis treatment. Regularity of dialysis treatment is very crucial for kidney patients because delay in such treatments would mean danger and may call for more expensive emergency procedures if not attended to immediately.
In 2007, NKTI records showed that of the 336 patients who were given transplantation procedures, 231 or 69% were pay patients and only 105 or 31% were service patients.
Prevention is best move
Prevention is the best move to counter the worsening problem on kidney disease in the country.
Kidney diseases are preventable, according to Dr. Uriarte. She emphasized the importance of early recognition of the causes to prevent or delay the development of kidney problems that usually end to kidney failure. That is why the REDCOP or Renal Disease Control Program under the NKTI, gives emphasis to the prevention aspect of controlling the spread of kidney diseases, according to Dr. Uriarte.
Playing a major role in the prevention of renal diseases, of course, is having a healthy lifestyle, which includes proper nutrition, regular exercise and timely physical check up.
The government appears to be giving less attention to combat the kidney disease problem. The Department of Health has no specific program to address this. Dr. Uriarte pointed out that no single centavo is given by the government in the campaign against renal diseases. She said that REDCOP depends on the funds that NKTI allocates to the program from the institution’s income.
Dr. Eleanor A. Jara, Executive Director of Council for Health and Development (CHD) said that it is the responsibility of the government to decisively exert the effort to address the worsening problem on renal diseases in the country given the prevailing economic difficulties confronting poor Filipinos these days.
Much more with the prevailing economic difficulties, the government must prioritize people’s health. This means increasing the share of health in the national budget from the less than one percent at present to as much as five percent of the country’s total production following the World Health Organization’s prescription. It also means unburdening the people in paying onerous debts incurred by the government and decreasing the budget for huge military spending.
Sources: info@worldkidneyday.org; www.sunstar.com.ph/static/dav/; sree1010.wordpress.com/2009/02/04;
abs-cbnnews.com/07/29/2008;
www.positivenewsmedia.net/.../Gov;
PIA Press Release, 12-04-2008; REDCOP/NKTI
History repeating itself? ... We'll Find Out Soon.
I’ll be very happy to see 10 cents a share …SOON!
“If we’re doing a good job in the Philippines and keeping people off dialysis in the Philippines, I see no reason why it shouldn’t sweep the rest of the world,” Moskowitz said.
Exclusive Reports
http://stlouis.bizjournals.com/stlouis/stories/2009/06/29/story10.html
GenoMed's earlier memorandum: the story in full>>>>>>>>>>>
Health
GenoMed, LaSalTech sign pact for preventive medicine venture
BACOLOD CITY, May 26 (PNA) - Bacolod internet services firm LaSalTech has been tapped by GenoMed, a US-based disease management company, as anchor partner in a venture that will introduce preventive molecular medicine to the Philippines and later to other parts of the world.
The GenoMed-Filipino venture will include GenoMed, Inc., a public US company, and LaSalTech Inc., a private Philippine company, their joint statement said.
Dr. David Moskowitz, GenoMed chief executive officer, arrived in Bacolod recently to sign a memorandum of understanding with LaSalTech represented by its chairman Bro. Rolando Dizon.
"The venture will include GenoMed's protocols to keep diabetic and hypertensive patients off the kidney machine, a telecommunication company to help us market and deliver our medical advice by cell phone, call centers to answer patients' questions in real time, and a generic drug company to offer the drugs we use at a low enough price for even the poorest Filipino to afford,” Moskowitz said in a statement.
He identified Globe Telecom Inc. as the telecommunications company that will help deliver GenoMed protocols by cellphone, and a catastrophic hospitalization insurance company as another potential partner.
Late last week, they began talks with additional potential partners, including a generic drug company and a chain of retail pharmacies.
“In the future, we'd like to add a network of discount physicians, clinical laboratories, dentists and optometrists. Retail pharmacists could check patients' blood pressures if doctors were too busy," Moskowitz said.
Dizon said LaSalTech is assisting GenoMed in the organization and management of the venture, including tapping of potential partners.
“LaSalTech will support David’s group to get things started,” he said, adding that the GenoMed-LaSalTech partnership is historic, and would be part of initiatives to make Negros Occidental go beyond its monocrop economy.
“We have to take very aggressive efforts in developing industries not dependent on sugar,” Dizon said.
For its part, GenoMed has acknowledged in its statement that foreign companies like theirs are limited by the Philippine law to a maximum of 40-percent ownership of any joint venture.
"If we succeed at a state-of-the-art, prevention-based healthcare solution for even the poorest Filipino, we will be able to export it to other countries, especially the US President Barack Obama has called for just such a solution.
"Unfortunately, I haven't found a single American partner despite a decade of searching,” Moskowitz said.
But in the Philippines, he said, he has found many potential Philippine partners after only a month.
Last month, GenoMed has announced that it has been in discussions to purchase Offshore HRM, a medical coding company which recently established a 200-person call center in Bacolod.
Moskowitz said GenoMed is engaged in two major activities, managing patients and doing research, and Offshore HRM will allow their company to manage patients on a large scale, and help them market to patients in the Philippines where there is an extremely high prevalence rate of diabetes.
Offshore HRM, which recently trained the Philippines’ first five medical coding professionals, will also recruit Filipino physicians and nurses and train them in GenoMed's algorithms to take care of paying patients. (PNA)
http://positivenewsmedia.net/am2/publish/Health_21/GenoMed_LaSalTech_sign_pact_for_preventive_medicine_venture.shtml
TMI proudly supports Genomed, Inc. and his CEO's remarkable initiative providing free on-line medical consultation.
http://www.technicalmedical.com/en/tmi_news.html
GenoMed in Discussions with Philippines Dept of Health to Eradicate Kidney Failure
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com
ST. LOUIS—August 25, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it has entered into discussions with the Department of Health of the Philippines to eliminate 95% of kidney failure from that country.
This follows on GenoMed's earlier memorandum of understanding with LaSalTech, a call center in Bacolod, Republic of the Philippines (RP). GenoMed will teach LaSalTech physicians its "recipe" and they, in turn, will recommend it to the 20 million adults with high blood pressure in the RP. An electronic record will be created for each patient, and GenoMed will supervise the operation from its St. Louis headquarters.
GenoMed and LaSalTech are also in discussions with a chain of retail pharmacies which would serve as the point of contact with the country's 20 million hypertensive patients.
Said Dr. Moskowitz, GenoMed's CEO, "We're delighted that the Department of Health of the Philippines is interested in supporting us. Their involvement is crucial."
Dr. Moskowitz continued, "If we succeed at a state-of-the-art, prevention-based healthcare solution for even the poorest Filipino, we will be able to export it to other countries, especially the US. President Obama has called for just such a solution. Unfortunately, Medicare has had no interest whatsoever in cutting 10% of its budget, or $35 billion a year."
Dr. Moskowitz ended by saying, "The Philippine government, on the other hand, simply can't afford to dialyze 20,000 new patients each year, and is committed to prevention. Our partner, LaSalTech, and Brother Rolando Dizon, its Chairman, helped make this happen. This is a great day for GenoMed's shareholders. We finally get a chance to show our stuff in a nation of 90 million."
About LaSalTech (www.lasaltech.com)
LaSalTech was the first Internet service provider in Bacolod, a city of 750,000 in Negros Occidental, the sugar-growing province of the Philippine Islands. Several years ago, LaSalTech entered the growing business of Call Centers. Brother Rolando Dizon, its Chairman, has been a trusted advisor to Philippine Presidents. He helped Cory Aquino overthrow former President Ferdinand Marcos.
About GenoMed (www.genomed.com)
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. GenoMed wants to prove that it can arrest diabetes, hypertension, and emphysema even in a developing country with scant resources like the Philippines. GenoMed intends to be the global healthcare provider of choice, especially for America's 50 million uninsured.
In the Media
Wednesday, 29 July 2009 08:47
Avoiding Dialysis with Dr. Moskowitz
Listen to an interview with Dr. Moskowitz on Natural Health Radio. Dr. Moskowitz discusses GenoMed's approach to preventing dialysis and kidney failure. To hear the entire interview, go to the Natural Health Radio website.
http://akcsm.com/radio/NHR-2009-07-29-Avoiding%20Dialysis-Kidney-Heart-Disease-with-Dave-Moskowitz.html
Date / Length: 7/23/2009 12:00 PM - 1 hr
A 'New Age' Tuskegee Medical Crime?
Harvard and MIT trained practicing nephrologist, and CEO/founder of OTC listed GenoMed, Inc., (http://genomed.com), David Moskowitz, MD, often finds himself at odds with mainstream medicine, including powerful St Louis hospital systems defending the 'sick care' recurring revenue streams associated with chronic renal dialysis treatment. Dr. Moskowitz claims he has the medical innovation, and documented research outcomes to prove his claim that kidney disease can be prevented, and even reversed - thus eliminating the patient's dependency on dialysis. Listen to Dr. Moskowitz.
http://www.blogtalkradio.com/2healthguru/2009/07/23/A-New-Age-Tuskegee-Medical-Crime
A 'New Age' Tuskegee Medical Crime?
Date / Length: 7/23/2009 12:00 PM - 1 hr
Harvard and MIT trained practicing nephrologist, and CEO/founder of OTC listed GenoMed, Inc., (http://genomed.com), David Moskowitz, MD, often finds himself at odds with mainstream medicine, including powerful St Louis hospital systems defending the 'sick care' recurring revenue streams associated with chronic renal dialysis treatment. Dr. Moskowitz claims he has the medical innovation, and documented research outcomes to prove his claim that kidney disease can be prevented, and even reversed - thus eliminating the patient's dependency on dialysis. Is Moskowitz a clinical 'disruptor' and medical innovator who threatens the mainstream, or an eccentric, perhaps unrealistic, practitioner having drunk the 'kool-aide' at perpetual odds with prevailing convention and medical standards? You be the judge.
http://www.blogtalkradio.com/2healthguru/2009/07/23/A-New-Age-Tuskegee-Medical-Crime
GenoMed’s Observation of Major Racial Difference in Prostate Cancer Confirmed
July 16th, 2009 by towardfivequot
GenoMed Inc announced today that it has received independent confirmation of an observation the Company orignally made in 2002 that prostate cancer behaves differently in ashen and black men. In black men, angiotensin II promotes prostate cancer, and ACE inhibitors are heedful. But in unblemished men, angiotensin II protects against prostate cancer, and ACE inhibitors promote prostate cancer.
In 2002, GenoMed published a surprising be produced end: that vim of angiotensin I-converting enzyme was positively associated with prostate cancer and PSA levels in African American men, but inversely associated with prostate cancer and PSA levels in Caucasians (Moskowitz DW. Is angiotensin I-converting enzyme a “master” affliction gene? Diabetes Technol Ther. 2002;4(5):683-711. Submit 9, p. 697; PDF put available at: http://www.genomed.com/pdf/is.angiotensin.pdf). This was the first suggestion that ACE inhibitors, which block the building of angiotensin II, might protect atrocious men against prostate cancer, but espouse prostate cancer in white men.
This observation was confirmed in a subsequent paper published by GenoMed last summer (Moskowitz DW, Johnson FE. The central task of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Unequalled Med Chem. 2004;4(13):1433-54), in which ACE inhibitors were found to increase the odds of prostate cancer in a predominantly white masculine veteran hospital population by a factor of 4.7 (Table 3). A “wiring diagram” fitting for prostate cancer in white men was proposed (Figure 12, p. 1446; PDF put within reach at: genomed.com/pdf/ACE_vertebrate_pathophysiology.pdf).
GenoMed’s surprising result was confirmed by Professor Marek Pawlikowski and his put together at the University of Lodz in Poland in move up published in late 2004, which GenoMed recently became aware of(medscimonit.com/pub/vol_10/no_11/4168.pdf).
Said Dr. David Moskowitz, GenoMed’s CEO and Chief Medical Policewoman, “Dr. Pawlikowski’s bracket acclimatized a prostate cancer cell line, DU-145, that was derived from a Caucasian male. They found in vitro exactly what we found in vivo using genomic epidemiologic and pharmacoepidemiologic facts in human compliant populations: angiotensin II surprisingly inhibited the growth of the Caucasian man’s prostate cancer cells. The legend probe whim be to look at if they observe the opposite result with the CRL-2422 prostate cancer chamber belt, which is derived from an African American patient. Our data predict that ACE inhibitors see fit slow the progress of the CRL-2422 prostate cancer cells, and angiotensin II command promote it, which is what angiotensin II does to most cancer lines.”
Added Dr. Moskowitz, “The public health message is actually undisputed: every white man on an ACE inhibitor should be more closely monitored for prostate cancer with a PSA be open every 6-9 months. On the other transfer manacles, every black gink with prostate cancer should consider taking an ACE inhibitor to slow down growth of the tumor.”
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause murrain. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many garden-variety diseases. The assemblage is currently marketing its protocols on the side of preventing kidney incompetent due to diabetes and consequential blood pressure, and delaying the progression of emphysema. The company is also conducting free clinical trials repayment for all cancers except prostate cancer in white men, as well as all viral diseases except herpes viruses. To enroll in GenoMed’s at large clinical burr under the saddle for West Nile virus, artlessly click on the West Nile virus together at http://www.genomed.com
Repository Harbor Affirmation
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) treatments. The words or phrases “ought to,” “should,” “may,” or be like expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could fall out materially from those projected in the dispatch looking statements as a denouement develop of a tally of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless in another manner required by applicable law, we specifically disclaim any demand to update any forward-looking statements to demonstrate occurrences, developments, unanticipated events or circumstances after the antiquated of such statement.
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
genomed.com
eps. Jeanette Mott Oxford and Rev. James Morris Endorse GenoMed's "Dialysis-Free in Five" Campaign
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
Lionel Nixon
Director, Field Operations
Legislative District 58
Missouri House of Representatives
lionelnixon@yahoo.com
Tel. 314-532-9902
The Honorable Jeanette Oxford
Representative, District 59
Missouri House of Representatives
jmo4rep@juno.com
Tel. 314-775-8940
ST. LOUIS—July 20, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today with pride that the Honorable Jeanette Mott Oxford and the Honorable James Morris have endorsed its campaign to make their districts at least 90% free of kidney disease by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. These two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
Both Rep. Oxford's district in south St. Louis and Rep. Morris's district in north St. Louis each contain about 35,000 people. Their districts are among the oldest, most population-dense, and most ethnically and economically diverse districts in the state, including significant numbers of families living in poverty.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is the key to eliminating 90% of new cases of kidney failure. We'll be working with primary care providers and pharmacists in Districts 58 and 59 to identify and treat patients with diabetes and high blood pressure. We'll adjust their medications intensively over a period of 2 to 3 months. By the end of 2010, we hope to have covered every patient in both Districts."
Dr. Moskowitz added, "The drugs we use are generic and cheap. GenoMed's fees are low enough for everybody in these Districts to afford. Preventive molecular medicine is actually quite inexpensive, about 100 times cheaper than dialysis."
Dr. Moskowitz ended by saying, "I'm thrilled that Rep. Oxford and Rep. Morris are courageously leading their Districts to better public health. They live Missouri's motto, Salus populi suprema lex esto ["Let the health of the people be the supreme law"]. Their Districts are lucky to have them."
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere. Please contact Dr. Moskowitz if you have one of these diseases.
Local business results for independent retail pharmacies near Saint Louis, MO - Change location - Back to results
Locator of pharmacies
http://member.express-scripts.com/web/pharmacyLocator/searchResults.do;jsessionid=0000Y16j03KyIVROYajHqzwOhbX:1499rvo79
A. Target Arnold - www.target.com - (636) 287-1055 - 3 reviews
B. Bangert Pharmacy - maps.google.com - (314) 831-3313 - 2 reviews
C. Prescription Plus Pharmacy - www.laduepharmacy.com - (314) 367-5558 - More
D. Target Fenton - www.target.com - (636) 326-1479 - 14 reviews
E. Williams Pharmacy - www.laduepharmacy.com - (314) 727-4854 - More
F. LDI Specialty Pharmacy - www.ldirx.com - (314) 652-4121 - More
G. Shop 'n Save - www.shopnsave.com - (314) 644-2908 - 1 review
H. Bellevue Pharmacy - www.bellevuerx.com - (314) 727-8787 - More
I. Medicine Shoppe - www.medicineshoppe.com - (314) 367-3009 - More
J. MD Pharmacy Inc - www.mdpharmacyrx.com - (314) 991-1111 - More
Retail Pharmacies City State Phone
Walgreens.com online only--not in stores 1.800.WALGREENS
drugstore.com online only
Clinton Rx Little Rock AR
Moon's Pharmacy Tifton GA
Medicap Co Bluffs IA
Oard Ross Rx Co Bluffs IA
Super Saver Rx Co Bluffs IA
Daves Health Mart Harlan IA
Osceola Drug Osceola IA
Cook Drugs Sigourney IA 515-622-3020
McDaniel Drug Washington IA
Slagle Phcy Wellman IA 319-64-6031
Best Buy Phcy Pittsfield IL 217-285-5515
Lee's City Drug Bastrop LA
Pearce Phcy Bastrop LA
Whits Phcy Bastrop LA
Price Right Phcy Calhoun LA
Hideaway Rx Monroe LA
Spats Phcy Monroe LA
Thompsons Rx Monroe LA
Causeys Pharmacy Natchitoches LA
Gardiners Pharmacy Natchitoches LA
University Phcy Natchitoches LA 352-9740
Mall Phcy Spring Hill LA
Albritton's Pharmacy Sterlington LA
No. Caddo Drug Vivian LA
Drennan's Rexall W. Monroe LA
Masons Phcy W. Monroe LA
Mr. Discount Drug W. Monroe LA
Bailes Rx, Village Rx, Dexter Rx Ann Arbor MI
Richardsons Rx Canton MI 734-981-3900
Ashland Phcy Ashland MO 573-657-2600
Ava Drug Co Ava MO 417-683-4127
Best Buy Phcy Bowling Green MO 573-324-3383
California Pharmacy California MO 573-796-2181
Laurie Health Mart Camdenton MO
Kinkead Phcy Centralia MO 573-682-2155
Flows Rx Columbia MO
Kilgore Pharmacy Columbia MO
Riddle Phcy Crane MO 417-723-5241
Eldon Drug Eldon MO 573-392-4588
Gainesville Phcy Gainesville MO 417-679-3511
Best Buy Phcy Hannibal MO 573-248-0170
St. Mary's Phcy Hannibal MO 573-221-3000
East End Phcy Jeff City MO 573-636-3733
Jeff City Med Group Jeff City MO 573-556-7780
Whaley's Med Center Jeff City MO 573-634-3606
Allen's Consumer's Phcy Joplin MO
Ken Reynolds Pharmacy Joplin MO
Pronto Pharmacy Joplin MO
HH Pharmacy Lake Ozark MO 573-964-6200
A&B Rx Shop Mexico MO 573-581-1350
Owl Phcy Milan MO
Mt Grove/Tilley Health Mt Mtn Grove MO
Ramey's Family Phcy Neosho MO
Paris Phcy Paris MO 660-327-4514
Hickey Drug Shelbina MO 573-588-2143
Convenient Care Rx Springfield MO 417-269-8880
George's Phcy Springfield MO
Grove Phcy Springfield MO 4178812910
Medicine Shoppe Phcy Springfield MO 417-866-3054
Zumwalt Phcy Stockton MO 417-276-3128
Beckwith Phcy Troy MO 636-528-8462
Warners Drug Unionville MO 660-947-2484
Bukarth Phcy Warrensburg MO 660-747-9171
Olson Brothers Pharmacy Minneapolis MN 612-929-0034
Mutual Drug stores
NC
Theile Phcy & Gift Alliance NE 308-762-4033
Hinky Dinky Pharmacy Auburn NE
Nat'l Home Medical Phcy Beatrice NE
Food 4 Less Phcy Fremont NE
Millers Phcy Fremont NE
Skagway Phcy Grand Island NE
Allen's Pharmacy Hastings NE
Blakes Pharmacy Louisville NE
Carl Baum Phcy Omaha NE
Kubat Phcy Omaha NE
Medicine Man Phcy Omaha NE
Phillips Phcy Omaha NE 402-731-4222
Swanton Phcy Swanton OH
Gladwynne Rx, Pierce Rx Altoona PA
Appleby's Pharmacy Mt. Union PA
McCutchan Phcy Atlanta TX
Miles Drug Atlanta TX
T & H Pharmacy Longview TX
Glenwood Pharmacy Texarkana TX
Tri State Phcy Texarkana TX 796-2841
Covington Rx Covington WA
Drug Emporium Charleston WV
House of Lords Science and Technology CommitteeSub-Committee II
http://www.parliament.uk/parliamentary_committees/lords_s_t_select/evidence2.cfm
Genomic MedicineOral Evidence
Audio and video webcast recordings of public meetings are available at www.parliamentlive.tv for 365 days.
------------------------------------------------------
Written Evidence
Memorandum by GenoMed Inc, April 2008
Summary
Genomic medicine will clearly revolutionize the practice of medicine. Medical genomics makes patients the ideal experimental subjects. For good reasons at the time, governments turned away from clinical research in the 1960s, preferring to focus on mechanistic studies in subhuman model systems. Clinical research was left to the research pharmaceutical industry. Unfortunately, the research pharmaceutical industry is on its last legs, and is in no position to develop genomic medicine.
To take full advantage of genomic medicine, the NHS will have to take a leadership role. Every GP will need to participate in a quality improvement (QI) program to better his or her patient outcomes. The existing technology is adequate. Because the research pharmaceutical industry already has more targets than it can handle, the NHS may need to become a “virtual” pharmaceutical company itself.
There will be obvious rewards, in terms of revenues and clinical outcomes, if the NHS takes such a proactive approach.
Introduction
The House of Lords Science and Technology sub-committee on genomic medicine is quite correct in believing that genomic medicine is a new field that could have tremendous impact on the daily practice of medicine. The sub-committee’s questions, reproduced below, are thoughtful. But they presume a rosier picture than actually exists.
The experience of a practitioner who still sees patients (as a general internist) and CEO of a medical genomics company may be valuable for the sub-committee to consider.
My comments are based on 15 years’ of wandering in the desert of genomic medicine (1-11). It has been a desert in every sense of the word: there has been virtually no research funding, no professional or academic collaboration, and no business model. And, of course, there is no scientific precedent—those in the field are making it up as we go along. The sub-committee’s questions about “regulation” make it clear that you understand that.
There is no doubt that genomic medicine will revolutionize the practice of medicine, sooner or later. So far, the medical establishment has managed to make it later (9).
The medical system, like any highly lucrative industry, profits from the status quo. Genomic medicine, by revealing the map for common diseases, makes it simple to inhibit disease pathways. It is certainly not rocket science! If over activity of an enzyme such as angiotensin I-converting enzyme (ACE) is behind a disease (2), then using an ACE inhibitor should help. Indeed, it does (1,5,7,10).
Genomic medicine already makes it possible for ordinary GPs to conquer diseases which still baffle government and non-profit funding agencies.
Most common diseases could be solved in the next few years. However, if the medical establishment has its way, they won’t be. Clinical outcomes won’t improve, but a few labs in a few prestigious universities will continue to be awarded enormous funds to perform mind-boggling but irrelevant tours de force, such as sequencing tumor genomes.
Today’s news illustrates the trend perfectly: http://www.genomeweb.com/issues/news/146282-1.html. The Wellcome Trust will spend
USD 60 million on whole genome association studies using the Affymetrix 1 million SNP (single nucleotide polymorphism) chip. This, notwithstanding the fact that earlier versions of Affymetrix’s chip containing 100K, 300K, 500K, and 600K SNPs haven’t worked, and that linkage techniques haven’t worked for polygenic diseases for the past 25 years (see below).
An alternative future
It is already possible, using the right fishing net, to find thousands of disease-associated SNPs. In 2004, we found roughly 5,000 SNPs for each of six different cancers in whites (Caucasians): breast, colon, lung, ovary, pancreas, and prostate. That was with a fishing net of some 20,000 SNPs that covered one-third of the genome. We now have a SNPnet™ of 80,000 SNPs that covers the entire human genome.
It must be said, however, that our SNPs come from a public database (dbSNP), and so apply only to Caucasian patients. To find SNPs for other ethnic groups—people of African ancestry, Asians, and mixed populations such as Brazilians—will require the construction of a separate dbSNP for each ethnic group.
The SNPs that we found are mostly located within 10 kb of a discrete gene. The disease-associated version of the SNP (susceptibility allele) presumably causes differential gene expression relative to the protective allele: over expression of oncogenes, under expression of tumor suppressors.
The traditional, mechanistic model of biomedical research would next require the construction of promoters containing the SNP, linked to reporter genes such as luciferase or CAT, in order to test exactly what the SNP does in various model systems. This could easily take 3-5 years and several hundred thousand pounds per SNP. Afterwards, the gene affected by the SNP would be explored for its role in tumorigenesis. This could easily take decades. For example, the role of BRCA1 and 2 is still not understood more than a decade after their discovery. The same is true for the CF gene, the PKD gene, etc. Discovery of these genes hasn’t yet led to drugs for treating patients.
Let us agree at the outset that the first goal of genomic medicine is improvement of clinical outcomes. Let us also agree that time is of the essence. Ultimately, a disease-causing gene is only significant if inhibiting it has a positive effect on the disease. Genomic medicine provides so many good targets that one can skip the promoter-bashing experiments mentioned above, and race ahead to designing drugs. Those with the lowest toxicity/efficacy ratio can be tested in animal models, without bothering to work out the exact cellular mechanism involved. That can be left to academic labs able to devote time to the subject.
In other words, the NHS can push for better clinical outcomes, while the MRC continues to fund basic research into mechanism.
An alternative focus: QI
Quality improvement (QI) is still missing from healthcare. In most industries, research is intimately tied to QI. Not so in medicine. Since 1948, as research has gotten more basic and less clinical, progress in clinical medicine has ground to a halt. More progress was achieved in medicine in the 1930s, arguably, than in all the years since the War on Cancer was declared in the US by President Nixon in 1972. Cancer survival rates have not improved for most common adult cancers. Nobody understands why stomach
cancer rates have been falling. The decrease certainly can’t be duplicated yet in other cancers.
The House of Lords Science and Technology sub-committee has a historical opportunity to use genomic medicine as a tool to improve quality in the NHS. The tool is certainly reliable enough. It will mean better patient outcomes and lower costs immediately—5% within the first 12 months of adoption, with greater savings over time. Cardiovascular disease can already be delayed, if not arrested (1,2). The remaining frontiers are oncology, followed by neurodegenerative diseases and crippling psychiatric diseases like schizophrenia and autism.
The NHS could use its unique resources to create the molecular diagnostics and genomics-based therapeutics of the next century or two. This would provide a revenue stream (river, really) for the NHS just when it needs fiscal help the most: as the Baby Boomers age and rely on it more heavily.
Molecular Diagnostics
The 5,000 SNPs we’ve already found for six cancers in whites are sufficient to predict 2/3 of cancers in whites. Little additional work is required—perhaps GBP 1.5 million over a 3 year period—to achieve FDA approval. A prospective trial could be performed at little cost over the next 5-10 years demonstrating that early diagnosis could actually lower cancer mortality.
ACE inhibitors or ARBs could be tried to delay or even prevent tumor growth (2) in patients detected to be at high risk for a particular cancer. So could one or more existing medications directed at some of the thousands of oncogenes we have already discovered.
In addition, already established radiological techniques (ultrasound, MRI) could be used to identify tumors while they were still small and surgically resectable for a cure.
Therapeutics
Until now, pharmaceutical companies have identified a disease pathway and then found inhibitors to interfere with the pathway. The emphasis has been on efficacy. Toxicity only becomes an issue later. This is backwards, since 99.9% of efficacious drugs fail because of toxicity. From a business point of view, this approach has been disastrous. The cost of bringing a new drug to market is now USD 1 billion and 12 years; it is only going up.
The few remaining research pharmaceutical companies can no longer tolerate any failure. They eschew basic science, instead asking biotechnology companies to present them with Phase III-approved drugs.
The only problem is that it costs GBP 250 million to get through Phase III. Nobody in their right mind would invest that much in a biotech company. Biotech companies are one-trick ponies whose drugs fail at the rate of 99.9%, the same failure rate as Big Pharma (research pharmaceutical companies).
With medical genomics, many thousands of participating genes can be identified at once. If one believes in the power of genomic epidemiology, then one can assume that most, if not all, of the associated genes are causative, as we have found for ACE (1-11). In other words, one can take efficacy for granted. Then one can screen out molecules based on toxicity. 99.9% of compounds will continue to fail because they are too toxic.
The 0.1% of compounds that pass toxicity assays can then be worked up for clinical trials. Starting with 3,000 drugs directed against 3,000 different targets should still result in 3 satisfactory drugs. Genomics can take the failure out of the pharmaceutical industry, and restore its pipeline.
Note that genotyping patients in order to market a toxic drug is a bad idea. It is much less expensive to discard a drug because of toxicity in an early in vitro assay than to (a) establish its mechanism of toxicity in humans; (b) find the human genetics behind this toxicity; (c) validate the toxicity test in a patient population, and (d) try to recoup all of the additional research costs by charging extra for the drug.
It still takes many years to bring a new chemical entity to market. In the meanwhile, already existing drugs can be repurposed, perhaps in combination. The genes associated with the disease determine which drugs to try. So many thousands of genes are involved with each disease that it’s already possible to find several dozen known drugs, with established toxicity profiles.
Stage IV cancer patients, whose prognosis is grim, could be used to test cocktails of already existing, non-toxic drugs. Cocktails may work better than single agents. Blocking multiple steps partially may limit the overall flux through the disease pathway specifically, effectively, and without toxicity, the goals of “kind” chemotherapy. Like the Lilliputians bringing down Gulliver with hundreds of weak ligatures, it may be possible to inhibit overall flux through a cancer-causing pathway using relatively weak inhibitors rather than the powerful cellular poisons currently employed.
Incomplete inhibition should limit toxicity. An inhibitor that blocked only 50% of the activity of a protein, combined with 6 other loose inhibitors, would nevertheless block overall flux through a pathway that relied on all 7 proteins by >99% (1/2[7] = 1/128 <1%).
New drugs
New chemical entities (NCE’s) can be developed if absolutely necessary—if no combination of already existing and known drugs works. But the cost and probable toxicity of NCE’s should make them the last resort of any healthcare system whose goal is QI.
Nevertheless, the UK is in an ideal position for drug discovery and drug development. It could easily harness the MRC and NHS to become a “peer-reviewed virtual pharmaceutical company™.” The MRC could continue to fund basic scientific programs into understanding drug mechanism, whilst the NHS could supply patients for Phase I-III testing.
Funding, the rate-limiting step, could come from financial institutions hitherto not involved in pharmaceutical research, but anxious to participate in the industry, now that Big Pharma is becoming extinct.
The research pharmaceutical industry has been undergoing massive consolidation since the late 1980s, so that only a few large pharmaceutical companies are left. Evidently, the industry can no longer support as many players as it used to. The reason for this is that managed care has been limiting the use of branded drugs since the early 1980s, such that they now occupy only 30% of the market. The use of generic drugs continues to increase every year.
The fewer the drug companies left, the larger they get. The larger they are, the more risk-averse they have become. Pfizer lost 20% of its market capitalization over the failure of its HDL-raising drug last fall. Drug companies are punished in the market-place for any failures. Their response has been to let biotech companies fail instead. As a result, Big Pharma’s pipelines have dried up. A huge vacuum is opening up in the pharmaceutical industry, precisely when genomics has finally made it possible to solve diseases.
Research partnership
The MRC and NHS could perform the preclinical and clinical work necessary for new drug discovery. Routine pre-clinical assays, such as absorption/detoxification/metabolism/excretion/toxicity (ADMETox), could be subcontracted to companies specializing in this work, as could chemical manufacturing. A company like GenoMed could easily supply the drug targets.
In return for its participation, the NHS could retain partial ownership of any intellectual property it helped to develop, especially new drugs. They would provide an ongoing revenue stream for the NHS during their patent life.
It light of the above discussion, I would like to try to answer the specific questions below.
Policy Framework
Who is in charge of setting and reviewing policy in this area?
In the US, the NIH and FDA.
Who provides scientific advice on policy development?
In the US, the NIH and White House Office of Science Technology and Policy. Congress is not terribly involved. The House of Lords Science and Technology Committee is to be commended for its involvement in genomic medicine.
Who monitors and anticipates potential scientific developments and their relevance to future policy?
In the US, it appears to be the NIH and HHS. The NIH just asked for outside guidance on genomic medicine, but it is pretty clear what they want to hear. The MRC would be just as closed-minded. Again, the House of Lords Science and Technology Committee is to be commended for taking up the topic themselves.
How effective are these mechanisms?
Not at all. Healthcare has remained stagnant for the past 28 years that I’ve been a practicing physician. Thiazide diuretics are still the first line treatment for hypertension. Just as in the 1920s, glucose control remains the mainstay of treatment for diabetes, yet complications arise at the same rates as 30 years ago.
Does the existing regulatory and advisory framework provide for optimal development and translation of new technologies?
Not at all. It takes 17 years for a new treatment to make its way into the clinic. I have personal experience that a new treatment doesn’t even get reported for going on 6
years now (1). Penicillin at least made the news soon after discovery, even if it wasn’t widely available for a decade. In this case, the drugs are already available, but nobody has breathed a word about the “recipe” for preventing end-stage renal disease. Healthcare has become, for all intents and purposes, anti-innovative at its core.
Are there any regulatory gaps?
Not particularly. What’s interesting is that not all tumor-expression data is useful: estrogen receptor status of breast cancers makes a big difference on treatment and prognosis, but not so EGFr status of breast and lung cancers, etc. Nevertheless, anti-EGFr treatments, although horribly expensive, are prescribed and paid for. If anything, the system is too lenient about paying for expensive medication which does little to improve clinical outcomes.
In what way is science and clinical policy decision-making informed by social, ethical and legal considerations?
They need to be informed by clinical considerations above all. Ethical, legal and social implications (ELSI) have, if anything, strangled genomic research in the US. Having to get informed consent for stored samples, when the patients may have already died, seems quite unnecessary. Who could possibly be hurt by using the tissue? Such misplaced solicitude has set the field back by several decades. Our duty is to patients with the disease now who need to be helped.
How does the framework compare internationally?
Internationally, the field of genomic medicine is in its infancy. No healthcare system has a meaningful QI program in place. Clinical outcomes are still not even reported, so how can they be improved? Samples are being stored in BioBanks, but there is no funding for any but a handful of labs to access them.
Research and Scientific Development
What is the state of the science?
A “master” disease gene has been found (2) but not applied to the population yet. Its application alone should save 5% of healthcare costs within the first 12 months, and perhaps 30% over 10 years (2).
Genes for 6 cancers in whites have been found, proving that GenoMed knows how to find causative genes for all cancers and perhaps all polygenic, common diseases. In theory, we could do this for any ethnic group, not just Caucasians, although we’d need to replicate dbSNP in each ethnic group.
What new developments are there?
Linkage disequilibrium approaches, which worked well for single-gene, so-called Mendelian disorders, have not worked at all well for polygenic diseases. A recent NEJM article, for example, found a single TGF-beta dependent gene after scanning cardiovascular disease patients for 600,000 SNPs (12). An association strategy using functional rather than neutral, “marker” SNPs is far better suited to polygenic diseases.
We have evidence that (a) there are some 10,000 participating genes per polygenic disease; (b) each gene may have more than one SNP involved; (c)
consequently, the signal from any one SNP is vanishingly small. In fact, there is no linkage disequilibrium between two SNPs only 17 bases apart. One SNP, at -789 in the ecNOS promoter, has a strong [p<10(-21)] association with Disease A (NIDDM, but not diabetic nephropathy), whereas another SNP at -772 has a similarly strong [p<10(-23)] association with Disease B (diabetic nephropathy) but not Disease A (NIDDM).
Finding disease-causing polymorphisms in a sea of 3 billion letters is like fishing for cod in the Atlantic Ocean. It helps to know where the fish like to congregate. Putting down nets every 10 meters across the Ocean is a very expensive and inefficient approach. Not surprisingly, whole genome association studies have yielded little for the past two decades. Yet the pediatric geneticists and genetic statisticians who succeeded at solving single gene diseases remain in control of the funding and the overall scientific strategy for adult, polygenic diseases.
What is the rate of change?
Little new since the CF gene was discovered 25 yrs ago. Affymetrix is putting out a 1 M SNP chip, since earlier versions haven’t worked. Ultimately, a 3 M SNP chip will be required, since that’s the minimum number of SNPs in the Caucasian human genome. There is a much more efficient way to find disease-associated SNPs!
Who is taking the lead in the consideration and co-ordination of research and the development of new technologies?
New technology is not necessary. Existing technology is adequate, if only there were adequate funding. Waiting for new technology would be like Isabella calling off Columbus until somebody discovered the diesel engine.
How effective is the policy and investment framework in supporting research in this area?
Rather ineffective. The same expensive approach to polygenic diseases that has failed for the past 25 years continues to be funded by both the governments of the UK and the US. Big Pharma has followed suit, compounding the loss of money and time. The field is considered to be too complicated for any other approach to work. If the experts all say that linkage disequilibrium is the only way to proceed, why should a private investor believe otherwise? How could a small start-up company possibly be right when the best and the brightest names in science are unanimous in pursuing the same, albeit unsuccessful, approach?
As a result, the field is in serious danger of going nowhere. When will government finally contemplate an alternative approach? Only after the 3 M SNP chip fails? Only after the 6 M SNP chip fails?
The biggest danger right now is that we’ll languish in the current state of clinical ignorance for another 50 years for lack of investment.
How does research in the UK compare internationally?
No better or worse than anybody else. Many countries are collecting BioBanks—Iceland, for the sole benefit of DeCODE; Estonia, etc. What nobody has yet done is actually solve any diseases. Or, if they’re solved (1), there has been no interest in applying the solution (9).
How much collaboration is there?
None as yet.
What are the current research priorities?
In oncology, the NIH plans to use the $300K sequencing machines left over from the genome sequencing effort to sequence individual tumor genomes—the equivalent of trying to inhibit the formation of snow by carefully photographing individual snowflakes.
What is the role of industry?
Industry is currently the public’s only hope—not Big Pharma, but small biotech companies like GenoMed. Pediatric geneticists and genetic statisticians are unfortunately in control of government funding, meaning that government is currently completely out of the competition. The only problem is that there is absolutely no funding for small biotech companies to carry the day.
How much cross-sector collaboration takes place?
Very little at present. Nil. There is intense disdain and distrust of industry by academia. On the other hand, academia has valuable—but replaceable—resources which could help industry. The good (and bad) news is that cancer patients can be found anywhere. Prestige matters very little. If the UK doesn’t embrace the plan I propose, they will become irrelevant bystanders. Any healthcare system in the world can carry out this plan, and partners in drug discovery and development can be found in many countries, including India, China, etc. The pieces of a “virtual” pharmaceutical company are easy to assemble. The technology is already available. Funding has become the rate-limiting step.
Data Use and Interpretation
Is genomic information published, annotated and presented in a useful way?
For most diseases, it doesn’t yet exist.
Should there be a common, public database?
Most of the $5-8 B a year pursuing disease-causing genomic polymorphisms would say no—that’s what they’re trying to discover. It would be like nationalizing the gold mines while the Forty-Niners were still flocking to California.
If so, who should fund, and have responsibility for, such an initiative?
The database will direct all of medicine for the next century at least. It will form the basis of molecular diagnostics as well as the pharmaceutical industry. For the government to run this program would require an extraordinary investment of funds and patience. Truly, it would be the “cathedral project” of the current century. But it would require a substantial change in direction. That’s unlikely without a test first. A competition to achieve pre-defined milestones over a short, say 2 year period, could be arranged, for example, identification of at least 10 disease-causing genes. Winners would be allowed to proceed; the losers would not.
Who should provide the framework for optimal evaluation of data and translational opportunities?
The data is easy to evaluate according to current scientific guidelines. There is a grave danger in making any one entity the Data Tsar, since in the history of science the Data Tsar usually turns out to be wrong. What is the sensitivity and the specificity of the test? Does the diagnostic chip actually lower mortality in a prospective study? Can the results be replicated by other groups? These are standard questions which can be published in any number of already existing journals.
What policy and funding mechanisms are in place for recognising and utilising potential opportunities?
Both in the US (NIH) and the UK (MRC), there is currently no policy for funding anything but me-too science. Nor is there any meaningful funding for clinical research. Genomic medicine creates hundreds of clinical hypotheses which all beg to be tested in actual patients.
Unfortunately, the NIH and MRC have left clinical trials to research pharmaceutical companies, beginning in the 1960s. Since the 1980s, generic drugs have captured more and more of the pharmaceutical market. Currently, 70% of the drugs purchased by healthcare plans are generic. As a result, the market for branded drugs is shrinking, and research pharmaceutical companies are going out of business. A massive consolidation has been underway in the research pharmaceutical market since the late 1980s. There have been virtually no Phase IV trials since the early 1990s.
This would be an ideal time to establish a clinically oriented funding mechanism. It should be part of the NHS itself, rather than the MRC. It should consist of the following components:
1. Reporting outcomes as they currently are.
Outcomes can’t be improved if we don’t know where we’re starting from. How well do diabetics do in Mr. X’s practice? How many go on dialysis? How long before dialysis? How many have heart attacks? How many lose their limbs? How many go blind?
The next level of inquiry will be comparative. Why do the diabetics in Mr Y’s practice do better than Mr X’s? Is there anything Ms Y does differently than Mr X? Can we all learn something from Ms Y, or will her hard-won insight be lost to the ages?
2. Pharmacoepidemiology.
Medical genomics raises a huge number of clinical hypotheses. For example, genomic epidemiology suggests that ACE inhibitors and ARBs may be useful for at least 150 common diseases. Review of patients’ prescriptions can quickly contribute information. Do patients taking an ACE inhibitor or ARB also take, for example, more or less tamoxifen than you’d expect for breast cancer? Tysabri for multiple sclerosis? Characteristic drug X for disease Y? If the odds ratio of taking an ACEI/ARB and characteristic drug X is above 1, then ACEI/ARBs lead to that disease. If the odds ratio is
less than 1, then ACEI/ARBs protect against that disease, in keeping with the genomic epidemiologic data. Prospective trials in actual patients with disease Y are next in order.
3. Molecular diagnostics.
(see discussion above)
4. Phase IV trials of existing medications, including “cocktails.”
(see discussion above)
5. New drug discovery and development.
(see discussion above).
Is other medical information recorded in a suitable format to allow optimal interpretation of genomic data?
If it’s on paper, it’s good enough. Obviously, electronic medical records would make it easier than having to pull charts. But there’s no point spending valuable time and money on developing electronic medical records. Use the money and time to find disease-causing genes and test new treatments instead.
Medicine has a long tradition of unnecessary make-work, such as the attempt at perfect blood glucose control in diabetics. Just because something can be done doesn’t mean that it should be done. Only if it drastically improves clinical outcomes should patients and physicians bother.
How should genomic data be brought together with other health information?
Genomic data should simply be part of the medical chart, like other health information. In principle, genomic data is no different from any other test result.
What are the implications of the generation and storage of genome data on personal data security and privacy, and on its potential use or abuse in employment and insurance? How should these be addressed?
Anti-discrimination laws in the US (the Americans with Disabilities Act) and the UK already prevent discriminating on the basis of a person’s genetic make-up. Health insurance in the UK doesn’t discriminate at all, since the NHS accepts all comers, regardless of pre-existing conditions.
Genomic data will actually make it easier to achieve better clinical outcomes. Insurance companies will become more profitable by using it. They would be silly to ignore it or, worse still, punish consumers because of it.
Translation
What opportunities are there for diagnostics, therapeutics and prognostics - now and in the future?
Tremendous opportunities for all three (please see above).
Who is responsible for translation to clinical practice?
At the moment, industry, since a business case can be made for improving patient outcomes and saving healthcare costs. And government has distanced itself from clinically relevant research since the 1960s.
Given the pace of technological advance, how 'future-proof' is healthcare investment in this area?
Finding disease-associated genomic polymorphisms is completely ‘future-proof’—they need only be found once in a species’ lifetime. They will not change. In other words, getting the answer right is worthwhile; the technology for getting the answer is irrelevant.
How does the UK compare to other countries and what lessons can be learnt?
At the moment, no better or worse off than anybody else. The first healthcare system that embraces a new approach will become the global leader in genomic-based medicine.
How meaningful are genetic tests which use genome variation data?
They are the best method of pre-symptomatic diagnosis.
What progress has been made in the regulation of such tests?
Nobody has them yet, so regulating them hasn’t been much of an issue. The BRCA1/2 tests were approved before it became apparent that they predict only 5% of breast cancer in white women. It had been hoped that they accounted for more sporadic cases. In general, families get their diseases in a different way than the bulk of the population, making linkage analysis even less useful for the general population.
A large, ethnically diverse healthcare system like the NHS is in a relatively unique position to work out accurate values for genomic tests for the world’s major ethnicities: their sensitivity, specificity, positive predictive value (PPV), negative predictive value, cost-effectiveness, effect on mortality, etc.
Biomarkers and Epidemiology
In what way do genome-wide association studies contribute to the identification of biomarkers?
Surprisingly little. See, e.g., the recent largely negative search for cardiovascular disease-causing genes using 600K SNPs published in the NEJM. A single TGF-beta dependent gene was unequivocally found (12). This was already obvious in 1992 (see 1 for ref.).
We’re told to wait for the 1 M SNP chip, just as we were told, when the 100K SNP chip failed, to wait for the 600K SNP chip. A 1 M SNP chip has marker SNPs roughly every 3,000 base pairs. Yet we have evidence that two SNPs only 17 base pairs apart are completely unlinked. Continuing to pursue the same, extraordinarily expensive approach without at least exploring other avenues is poor scientific strategy. Any scientist running his/her own laboratory would have given up on this particular line of attack long ago. It’s surprising to me that the UK, which prided itself on clever rather than brute-force experimental approaches when I was a student at Oxford in the mid-1970s, is still copying everybody else 25 years later.
How is the study of genetic factors and biomarkers integrated for translational purposes? A healthcare system that wanted to improve clinical outcomes could easily do this. But the first step would be to try to optimize clinical outcomes. The NHS doesn’t even report outcomes yet. No health system does. Reporting health outcomes would be an invaluable first step for quality improvement (QI), irrespective of genomic medicine.
What impact will genomic data have on data emerging from projects such as UK Biobank, Generation Scotland and other biobanks?
The Biobanks are not as useful as directed patient collections for specific diseases. A directed strategy would be much more efficient than exhaustive sample collection. Collecting samples does not solve the disease.
Use of genomic information in a healthcare setting
What impact will genomic information have on the classification of disease?
It will be critical as an early warning system for otherwise lethal diseases, such as cancer. It may help in the treatment of currently untreatable diseases. But it won’t necessarily help much with classification—other than to show that one gene may be involved in many different diseases.
How will it affect disease aetiology and diagnostic labels?
A single gene can cause multiple diseases. Genomics may break down barriers between clinical divisions. Genomics is tending to “lump” diseases together, rather than slice diseases into ever finer categories.
How useful will genomic information be as part of individualised medical advice?
Critical for assessing cancer risk and detecting cancer while still early. Probably not very important in determining specific treatment. We’ve found that everybody responds to an ACE inhibitor, for example, regardless of ACE I/D genotype (1). Similarly, people without a particular SNP in gene X may still respond to an inhibitor of gene X simply because the overall disease pathway involves gene X. We still don’t understand what a disease pathway looks like, whether it’s common to all patients with the same clinical diagnosis, etc. We’ll only know how disease pathways work once we get clinical experience trying to interrupt them. To pretend otherwise at this point would be dishonest.
What provisions are there for ensuring that the individual will be able to understand and manage genomic information, uncertainty and risk?
The general provision that any information be told in a way that a 2nd grader can understand it. Genomic medicine will be the GP’s duty to explain to the patient. Those establishing new tests will need to make the test intelligible to the GP.
Should there be a regulatory code (mandatory or voluntary) covering the provision of this advice?
There’s no sense regulating something that doesn’t even exist yet. Plus, the people presumably doing the regulating—trained genetic counselors—studied Mendelian
genetics. Polygenic diseases have not been fully characterized yet, let alone understood. So it makes little sense to have Mendelian geneticists regulating people on material they don’t understand themselves.
What are the implications of developments in genomic technologies for the training of medical specialists and other health professionals?
With luck, genomics will elevate the GP and make sub-specialists redundant.
Are there any gaps that need addressing?
Geriatrics, but genomic medicine doesn’t change population demographics.
What is the assessment and planning for future needs in capacity?
If genomics can increase life expectancy by a decade, people are going to have to agree to die at home once they reach 100, rather than in hospital. That’s the only way for a healthcare system to save money.
References
1: Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther. 2002;4(4):519-32.
PMID: 12396747. (For PDF file, click on paper #1 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
2: Moskowitz DW. Is angiotensin I-converting enzyme a "master" disease gene? Diabetes Technol Ther. 2002;4(5):683-711. PMID: 12458570 (For PDF file, click on paper #2 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
3: Moskowitz DW. Is "somatic" angiotensin I-converting enzyme a mechanosensor? Diabetes Technol Ther. 2002;4(6):841-58. PMID: 12685804 (For PDF file, click on paper #3 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
4: Moskowitz DW. Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes. Diabetes Technol Ther. 2003;5(2):189-99. PMID: 12871609 (For PDF file, click on paper #4 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
5: Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)
6: Moskowitz DW. Acute oxygen-sensing mechanisms. N Engl J Med. 2006 Mar 2;354(9):975-7. PMID: 16510756
7: Williams RM, Moskowitz DW. The prevention of pain from sickle cell disease using trandolapril. J Natl Med Assoc 2007 Mar; 99(3):276-8 (http://www.nmanet.org/images/uploads/Publications/CR0276.pdf)
8: ACE inhibitors and ARBs (angiotensin II receptor blockers) may turn out to be general viral antidotes, as described in Section 2151 of the Project BioShield II Act of April 28, 2005 (http://www.govtrack.us/congress/billtext.xpd?bill=s109-975), reproduced below:
CHAPTER 5--REPORT AND ADMINISTRATION
SEC. 2151. REPORT TO CONGRESS.
Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response.
9. Moskowitz, DW. Promoting dialysis alternative. Letter. ACP Observer, Dec. 2006 (http://www.acponline.org/journals/news/dec06/letters.htm)
10. Daily KC and Moskowitz DW. Unusually long MS remission with losartan. (Submitted).
11. Moskowitz DW. Hypertension, thermotolerance, and the "African gene": an hypothesis. Clin Exp Hypertens. 1996 Jan;18(1):1-19. PMID: 8822230
12. Samani NJ et al. Genomewide Association Analysis of Coronary Artery Disease. New Engl J Med 357(5):443-453, August 2, 2007.
Followers
|
41
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1326
|
Created
|
11/27/01
|
Type
|
Free
|
Moderators |
Shares outstanding per the transfer agent 02/02/09: 221,170,711
04/27/09: Genomed Swine Flu Play?
http://www.cyperus.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-15-2004/0002090287&EDATE=
http://www.medicalnewstoday.com/articles/34202.php
http://www.medicalnewstoday.com/articles/10713.php
Annals Publishes GenoMed, Inc. Approach To Avian Influenza
http://www.biospace.com/news_story.aspx?NewsEntityId=34330
http://www.medicalnewstoday.com/articles/33141.php
GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
GenoMed’s WNV Treatment May Work for Avian Influenza
http://avianflu.futurehs.com/?p=804
Genomed - Preventive Molecular Medicine
Before posting on this board, please read the GMED BOARD LAW at the bottom of this iBox.
GenoMed, Inc.
9666 Olive Blvd.
Suite 310
St. Louis, MO 63132
USA
314-983-9933
Ticker Symbol: GMED
Website: http://genomed.com and http://www.thelatestmedicaltreatment.com/
GenoMed is a Next Generation DMtm company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics--the study of which genes cause disease--into clinical practice. We combine biotechnology with Disease Management (DM). We develop new and better drugs, we use existing drugs for new disease indications, and we uncover disease before symptoms arise. By studying disease genes, we hope to make medicine more proactive and disease prevention more effective.
Our goal is nothing short of a medical revolution: we aim to change the way medicine is practiced. Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be a leader in the Era of Genome-based Preventive Molecular Medicine. Indeed, we believe that our patent-pending ACE inhibitor treatment, if widely applied, could save 50% of healthcare costs worldwide over the next decade.
per http://www.thelatestmedicaltreatment.com/,
"Our goal is nothing short of a medical revolution: we aim to change the way medicine is practiced. Instead of waiting for symptoms to develop, we intend to diagnose disease before any signs are visible. Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be the leader in the Era of Genome-based Preventive Molecular Medicine."
12/08:Is the Era of Personalized Medicine (Almost) Really Here?
"...President-Elect Obama is promising to throw his weight behind personalized medicine in the upcoming administration says AP"
"...while in the Senate, Obama sponsored a personalized medicine bill himself that promoted the R&D necessary to develop genetic tests for certain drugs and to develop a "biobank" of information for researchers and federal funding for this research as well, says AP."
source: http://blog.bioethics.net/2008/12/is-the-era-of-personalized-medicine-almost-really/
"Master" Disease Gene/Fountain of Youth?
GenoMed has discovered and applied for patent protection on a treatment that could have wide-ranging use for over 150 common diseases that currently carry a dismal prognosis. These include diabetes and its complications (which affects 20 million in the United States alone), high blood pressure and its complications (which affects 60 million in the U.S.); emphysema and other smoking-related diseases; and many other serious diseases, including infection with HIV and progression to AIDS, common solid cancers such as lung, colon, pancreas, liver, and kidney; cancers of the blood-stream such as chronic leukemias, multiple myeloma, and lymphomas; and immune-mediated diseases such as multiple sclerosis, degenerative joint disease (osteoarthritis) and rheumatoid arthritis.
GenoMed has found that over-activity of a single enzyme, angiotensin I-converting enzyme ("ACE"), may be behind these diseases. The logical treatment is effective inhibition of the ACE enzyme, using the correct dose of the correct ACE inhibitor. As a class, ACE inhibitors have been in widespread use since the 1970's, and have a very well-known safety profile. The company has so far had dramatically positive results in the following diseases:
1. Chronic kidney failure due to adult-onset diabetes
2. Chronic kidney failure due to high blood pressure
3. Poor circulation due to high blood pressure
4. End-stage emphysema
5. Psoriasis
GenoMed Completes First Version of Healthchip(r) for Cancer Prediction
ST. LOUIS, April 20, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has constructed a Healthchip® which may serve as an early warning system for the top six common cancers in whites: breast, colon, lung, ovarian, pancreatic, and prostate.
GenoMed's Healthchip® is made up of many single nucleotide polymorphisms (SNPs). In internal testing, the Healthchip® correctly identified the type of cancer in 85% of cases. None of the normals were misdiagnosed. More testing is required to confirm these results.
The well known breast cancer genes, BRCA1 and BRCA2, account for only 5% of breast cancers in white women. GenoMed's SNPs may pick up the remaining 95% of sporadic breast cancer cases in white women, i.e. in women without a strong family history of breast cancer.
Said Dr. David Moskowitz, GenoMed's chairman and chief executive officer, "It's important for any screening test to have as few false positives as possible. GenoMed's Healthchip® currently has none."
The test for mutations in the BRCA1 and BRCA2 genes costs about $1,200, has been available for about a decade, and has been reimbursed by a handful of insurance plans for the past few years. GenoMed's test is currently available for research purposes only, and is not yet reimbursable by any health plan. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com to inquire about GenoMed's testing program.
SEC Filings - GenoMed files
http://www.b2i.us/profiles/investor/sec.asp?BzID=571
GenoMed has the solution to the coming pandemic.
April 19, 2006 - GenoMed to Offer Free Mumps Trial http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={3D6172DA-7BE1-495A-9696-E13B4F9E8A9A}&am....
February 1, 2006 - GenoMed's Formula for Better Healthcare at Half the Price = GenoMed + President Bush's HSAs
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14065&GoTopage=1&am....
January 11, 2006- Turkish Brothers With Virus But No Symtoms Confirm GenoMed's Approach to Bird Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=13849&GoTopage=1&am....
December 29, 2005 - Q & A page. Many of us find it incredible that your solution to the Avian flu problem has not been accepted in mainsteam circles. We are sure it will be in thefuture. Have you been able recently to make progress in this area?
http://www.b2i.us/profiles/investor/QAForum.asp?BzID=571
November 14, 2005 - 'Cytokine Storm' Paper Confirms GenoMed's Approach to Avian Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12769&GoTopage=1&am....
September 16, 2005 - GenoMed's WNV Treatment May Work for Avian Influenza; GenoMed Tries to Help President Bush Avoid Avian Flu Mistake
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=11695&GoTopage=2&am....
scientists say bird flu provokes an excessive immune reaction (Reuters)
Investor Relations:
David Moskowitz MD, MA(Oxon.), FACP
Chief Medical Officer
dwmoskowitz@genomed.com
Phone: (314) 983-9933
Fax: (314) 983-9939
News:
June 26, 2006- GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=16056&GoTopage=1&am....
June 21, 2006- GenoMedGenoMed CEO Invited to Lecture at University of Chicago about Bird Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15953&GoTopage=1&am....
June 5, 2006- GenoMed, West Nile Virus, and Counting Crows
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15818&GoTopage=1&am....
May 2, 2006- MO Rep. Mott Oxford Congratulates GenoMed on Reversing Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15384&GoTopage=1&am....
April 12, 2006- GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15006&GoTopage=1&am....
March 9, 2006- GenoMed Agrees to Distribute Healthcare to India for Under $150 Per Patient Per Year
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=15006&GoTopage=1&am....
March 1, 2006- GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14428&GoTopage=1&am....
February 23, 2006- GenoMed Trial Results: Multiple Sclerosis—From Two Relapses a Year to None in 16 Months
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14330&GoTopage=1&am....
February 22, 2006- GenoMed Trial Results: Sickle Cell Disease—From Daily Pain to None
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14329&GoTopage=1&am....
February 21, 2006- GenoMed Trial Results: HIV--Viral Load Goes to Zero
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=14327&GoTopage=1&am....
November 28, 2005 - GenoMed Considers Offering Low-Cost Health Insurance to America's Uninsured
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=13128&GoTopage=1&am....
November 14, 2005 - 'Cytokine Storm' Paper Confirms GenoMed's Approach to Avian Flu
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12769&GoTopage=1&am....
October 28, 2005 - GenoMed Scores 14th Victory Treating Neuroinvasive West Nile Virus in Humans
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=12531&GoTopage=2&am....
September 16, 2005 - GenoMed's WNV Treatment May Work for Avian Influenza; GenoMed Tries to Help President Bush Avoid Avian Flu Mistake
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=11695&GoTopage=2&am....
July 26, 2005 - GenoMed Submits 50th Provisional Patent
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10830&GoTopage=2&am....
July 25, 2005 - GenoMed's Observation of Major Racial Difference in Prostate Cancer Confirmed
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10805&GoTopage=2&am....
July 13, 2005 - GenoMed Joins International Disease Management Alliance
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10498&GoTopage=2&am....
June 29, 2005 - GenoMed CEO Testifies Before Missouri Medicaid Reform Commission
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10216&GoTopage=2&am....
June 24, 2005 - GenoMed's WNV Treatment Abruptly Stopped, Patient Deteriorates
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=10147&GoTopage=3&am....
June 21, 2005 - GenoMed's Method to Prevent Most Kidney Dialysis Featured on IKIDNEY.COM
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9973&GoTopage=3&....
June 16, 2005 - GenoMed Treats Its First Presumptive West Nile Virus Patient of 2005
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9944&GoTopage=3&....
June 14, 2005 - GenoMed to be Awarded Second Patent, for Treating Acute Kidney Failure Without Dialysis
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9926&GoTopage=3&....
June 07, 2005 - GenoMed Announces 3rd Year of its West Nile Virus Trial; Now Part of BioShield II
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9862&GoTopage=3&....
May 26, 2005 - GenoMed to be Awarded First Patent: Hastening Lung Maturation in Newborns.
http://biz.yahoo.com/prnews/050526/cgth017.html?.v=10
May 03, 2005 - BioShield II Specifically Mentions GenoMed's Antiviral Approach.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8988&GoTopage=4&....
April 20, 2005 - GenoMed Completes First Version of Healthchip(r) for Cancer Prediction.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=9175&GoTopage=1&....
April 07, 2005 - GenoMed Offers Treatment to Combat Effects of Smoking.
http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={819BED6A-86DF-4818-A5AD-D832773CD614}&am....
April 05, 2005 - GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care
http://tools.thestreet.com/rmy/quotes.html?pg=qcn&guid={D1BC492A-545E-4CC5-9876-B2C310E49644}&am....
Mar. 31, 2005 - GenoMed, Inc. Issues Clarification
GenoMed, Inc. (Pink Sheets: GMED) has been advised that one or more Internet websites are recommending the purchase of the Company's stock, and that unsolicited electronic mail has been circulated encouraging the purchase of the Company's stock. The Company is not responsible for, and is unaware of the source of, such Internet activity and makes no comment about the accuracy of such communications. The Company's management does not comment on research reports or rumors concerning the Company's activities or stock price.
Mar. 24, 2005 - GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter
http://www.wallstreetreporter.com/profiles/GenoMed.html
Mar. 10, 2005 - GenoMed, Inc. Says New Medicare Legislation May Accelerate Acceptance of Its Therapy.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8721&GoTopage=1&....
Mar 03, 2005 - GenoMed Finds Thousands of Cancer-Associated Genotypes.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8643&GoTopage=1&....
Feb 23, 2005 - GENOMED THERAPY COULD REDUCE HELATHCARE COSTS.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8521&GoTopage=1&....
Feb 15, 2005 - GENOMED INC. FILES PATENT APPLICATION Company Identifies Two Additional Cancer-Related Genes.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=8280&GoTopage=1&....
Jan 20, 2005 - West Nile Virus Encephalitis Victim's Family Wants to Increase Public Awareness of GenoMed's Clinical Trial.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7901&GoTopage=1&....
Jan 13, 2005 - GenoMed Finds Two Genes Linked to Common Cancers.
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7910&GoTopage=1&....
Dec 13, 2004 - UC Irvine Researcher Confirms GenoMed’s Patent-Pending Discovery: ACE is Major Aging Gene, ACE Inhibition is Partial “Fountain of Youth”
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=7652&GoTopage=1&....
July 13, 2004 - GenoMed and Italian NIH to Collaborate in Finding a Cure for Bird Flu in Poultry
http://www.b2i.us/profiles/investor/ResLibrary.asp?BzID=571&ResLibraryID=6534&GoTopage=7&....
July 06, 2004 - GenoMed Applies for Listing on American Stock Exchange
Recent Publications
1. From Pharmacogenomics to Improved Patient Outcomes: Angiotensin I-Converting Enzyme as an Example
http://www.genomed.com/pdf/diabetes.technology.therapeutics.pdf
2. Is Angiotensin I-Converting Enzyme a "Master" Disease Gene?
http://www.genomed.com/pdf/is.angiotensin.pdf
3. Is "Somatic" Angiotensin I-Converting Enzyme a Mechanosensor?
http://www.genomed.com/pdf/Is.ACE.a.Mechanosensor.pdf
4. Pathophysiologic Implications of Angiotensin I-Converting Enzyme as a Mechanosensor: Diabetes
http://www.genomed.com/pdf/Pathophysiologic.pdf
5. Why AT1R blockade makes sense for SARS
http://www.genomed.com/pdf/AT1RSARS.pdf
6. The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
http://www.genomed.com/pdf/ACE_vertebrate_pathophysiology.pdf
****GMED BOARD LAW: The main objective for this moderated board is to keep it free of posts which do not add value to the discussion of the stock, while keeping the board balanced, clean, on-topic with due diligence kept up to date. All posts here should stay focused on GMED, along with any other information which pertains to or affects GMED, i.e. competition, FDA guidance, current events, T/A analysis. Pro and con debate is encouraged as long as the opinions are kept on a mature level, with the omission of personal jabs.
ZERO TOLERANCE LEVEL FOR PERSONAL ATTACKS, PESONAL ISSUES, POLITICAL INNUENDO, SPAM, MULTIPLE ALIASES, DUPLICATE POSTS OF THE SAME SUBJECT MATTER, REDUNDANCY, OBVIOUS BASHING, OBVIOUS BOARD DISRUPTION TACTICS, IRRELEVANT OFF-TOPIC SUBJECT MATTER, ADVERTISING, ARGUING.
POSTS WILL BE REMOVED WITHOUT DEBATE OR QUESTION. PLEASE DON'T FEED THE ANIMALS!!!!
If moderation of this nature offends you, then this board is not for you.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |